Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...

DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi ...

Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables ...

Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

The technique is called in vivo CAR-M therapy. "The nomination of the two autoimmune targets is a significant milestone in ...

The red represents an mRNA strand. Photo credit: www.cancer.gov Primrose Bio, a San Diego biotechnology company that aims to improve the manufacture of next-generation therapeutics, has begun a ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

Moderna's ability to launch differentiated mRNA therapies beyond covid, ranging from prophylactic vaccines for other respiratory diseases to cancer treatments, will be key to establishing a moat ...